spacer
home > ebr > autumn 2017 > enhanced effects
PUBLICATIONS
European Biopharmaceutical Review

Enhanced Effects

Cellular therapies – such as treatment with mesenchymal stem cells (MSCs) or, recently, with genetically adapted T-autologous (Ta) cells – are coming of age and have exhibited their efficacy for selected indications in numerous preclinical trials. Many have received first approvals or are likely to in the near future. MSCs have been approved for selected indications in Canada as well as New Zealand, and at least one chimeric antigen receptor (CAR) T-cell product has gained a unanimous positive review by the FDA advisory committee.

The cross-section of medical devices and cellular therapies has been explored and utilised for some time; for example, cells have been embedded in collagenous foams to secure their location, or catheters have been employed to facilitate targeted delivery of cells.

For biologics and small molecules, this cross-section is perhaps not as clearly visible, yet it has transpired that combinations may yield massive improvements, as demonstrated in preclinical studies. Hence, this appears to be an opportunity worthy of exploration due to its benefits as well as its practical, quality and regulatory implications.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Christian van den Bos founded Mares Ltd in 2007 to accelerate the development of regenerative medicinal products and currently serves as its Managing Director. He underwent postdoctoral training at Cold Spring Harbor Laboratories, US, and earned a PhD at the University of Münster, Germany, as well as an MSc at the University of Oxford, UK.
spacer
Dr Christian van den Bos
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Haselmeier Relies on DQIQOQ Qualified Testing Machines and Zwicks Materials Testing Laboratory

Haselmeier is a leader in the development and manufacture of innovative self injection devices. Numerous international pharmaceutical manufacturers are customers of this Swiss company. In addition to testing production batches of pen injectors, Zwick's Materials Testing Laboratory offers DQ/IQ/OQ qualification and measurement system analysis of the testing system used for the tests.
More info >>

White Papers

Securing the Global Pharmaceutical Supply Chain against the Threat of Counterfeit Drugs

World Courier

With a fully integrated GxP-compliant transport, storage and distribution system in place and over 140 wholly owned ISO 9001 - certified offices in more than 50 countries, WORLD COURIER, an AmerisourceBergen® company, is the world’s largest and most experienced provider of specialty courier services. It is uniquely positioned to meet the most demanding industry requirements for managing the global distribution of time - and temperaturesensitive pharmaceutical products and IMPs used commercially or in clinical trials.
More info >>

 
Industry Events

SCOPE Europe: Summit for Clinical Ops Executives

16-17 October 2018, Barcelona, Spain

Building on the success of its long-running US-based counterpart, Summit for Clinical Trials Operations Executives Europe (SCOPE Europe) is a two-day event serving clin ops execs, functional heads, category managers and those responsible for the planning and management of clinical trials in Europe and the Rest of the World.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement